# Shaun Noorian (Empower Pharmacy CEO) - GLP-1s, Patents, and the Future of Compounding

Page: https://stenobird.com/podcast/hims-house-7026583/shaun-noorian-empower-pharmacy-ceo-glp-1s-patents-and-the-future-of-compounding
Text version: https://stenobird.com/podcast/hims-house-7026583/shaun-noorian-empower-pharmacy-ceo-glp-1s-patents-and-the-future-of-compounding.md
Podcast: [Hims House](https://stenobird.com/podcast/hims-house-7026583)
Published: 2025-08-19T12:23:36+00:00
Episode link: https://podcasters.spotify.com/pod/show/jonathan-stern1/episodes/Shaun-Noorian-Empower-Pharmacy-CEO---GLP-1s--Patents--and-the-Future-of-Compounding-e3egqle
Audio file: https://anchor.fm/s/10e9c0874/podcast/play/114894958/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-1-2%2F417288022-44100-2-047ab2c3f92f26dc.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/shaun-noorian-empower-pharmacy-ceo-glp-1s-patents-and-the-future-of-compounding
Duration seconds: 3913

## Resource

In Episode 42 of Hims House, Jonathan Stern and Patrick Lester (Bayside) sit down with Shaun Noorian, founder & CEO of Empower Pharmacy, the world’s largest compounding pharmacy. We dig into why rumors about 503Bs “ramping up GLP-1s” may be misleading, how Empower is challenging Eli Lilly on tirzepatide patents, and the broader fight over compounding. We also how Trump’s new administration - RFK Jr. at HHS, and Marty Makary at FDA - could reshape the industry. We close with the MFN pricing backdrop under the new administration. All along the way, Noorian makes the case that compounding is not a loophole but a critical, highly regulated part of healthcare, and looks ahead to its future in hormone therapy, peptides, longevity medicine, and sleep health. 00:00 – Intro 00:52 – Empower’s mission: personalized medicine at scale 03:07 – GLP-1 rumors: are 503Bs ramping? What’s actually legal 09:21 – 503A vs. 503B compliance 19:14 – The Eli Lilly v. Empower lawsuit 27:04 – MFN pricing, EO chatter & compounding 33:11 – Hims’ impact on the industry: awareness, lobbying & demand 37:15 – HRT, peptides, longevity 39:59 – Sermorelin explained 41:32 – Bad actors vs. legitimate compounders 43:08 – Odds: percent chance of FDA action against compounders Get full access to Hims House at himshouse.substack.com/subscribe

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/shaun-noorian-empower-pharmacy-ceo-glp-1s-patents-and-the-future-of-compounding/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/hims-house-7026583/shaun-noorian-empower-pharmacy-ceo-glp-1s-patents-and-the-future-of-compounding.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.